Ichnos Sciences to present at AACR

By The Science Advisory Board staff writers

March 29, 2022 -- Biotechnology company Ichnos Sciences will present preclinical data for ISB 1442, a bispecific antibody, at the American Association for Cancer Research (AACR) annual meeting, held April 8-13, 2022.

ISB 1442 is currently being investigated in blood cancers, including relapsed/refractory multiple myeloma, T cell acute lymphoblastic leukemia, and acute myeloid leukemia. The company said that enrollment in the first-in-human ISB 1442 trial is expected to start in mid-2022.

The poster is titled "ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38+ malignancies" (2903/18).


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.